American Heart Association

outcomes research

VITALITY-HFpEF: Designed to test the hypothesis that vericiguat may improve physical functioning in patients with HFpEF

Contributor: Emily Cendrowski

VITALITY-HFPEF is a trial underway which will evaluate the efficacy of vericiguat in HFpEF patients by using the KCCQ-PLS (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score) as a primary endpoint. The choice of this primary endpoint will make it the first HF trial utilizing a quality of life, patient-reported outcome (PRO) as a primary endpoint. There remains a need for medications which improve mortality and functional status for patients with HFpEF. An ongoing area of research involves the cyclic guanosine monophosphate (cGMP) pathway.

Visual Abstract: Validity of Performance and Outcome Measures for Heart Failure

Contributor: Ike Chinyere

Validity of Performance and Outcome Measures for Heart Failure

Study Link: Validity of Performance and Outcome Measures for Heart Failure

HF patient death leads to poor spousal outcomes

Contributor: Elise Vo

Being the spouse of a HF patient is challenging. In a recent study, Dunlay and colleagues explored the link between spousal health and HF patient outcomes. Interestingly, spousal health did not correlate with HF patient death or hospitalization. However, spouse caregivers experienced worse outcomes following the death of their HF partner.

Olmsted County residents were screened for HF between 2002-2012 using ICD-9 codes. 905 patients met study criteria, 586 (65%) males with mean age of 73.3, 96% Caucasian, and average LVEF 47.7%. The spousal characteristics were: 584 (65%) female, mean age of 71, and 96% Caucasian. HF patient charts were reviewed for marriage.

Precision medicine for cardiac resynchronization: Predicting quality of life benefits

Contributor: Nicholas Hawkes

Who benefits from cardiac resynchronization therapy (CRT)? Studies show that among select HF patients CRT improves longevity, ventricular remodeling, and quality of life (QoL). The precision medicine approach asks the question, “Are there individual factors that predict QoL improvements?” Spertus and colleagues demonstrated that age, baseline QoL, and QRS duration predict individual QoL after CRT.

Decreased incidence yet increased prevalence of heart failure among Medicare beneficiaries

Contributor: Chris Sobowale

Over 6.5 million Americans have HF, costing over $31 billion annually. Those are big numbers, but what is the trend? Berry et al explored the epidemiology of heart failure by examining fee-for-service Medicare patients from 2002-2013. This was presented as a late-breaker at the AHA Scientific Sessions 2017 with simultaneous publication in Circulation: Heart Failure – the new editor teams’ first simultaneous publication – but hopefully not our last!